Biocon Limited

360 ONE bought 626,000 shares of Biocon Limited for ₹25.04 Cr at ₹400.00 apiece in a block deal.

A leading biotechnology company engaged in the manufacture of innovative pharmaceutical products and research services across multiple therapeutic areas. Biocon specializes in biologics, biosimilars, and small molecule drugs, serving patients in oncology, immunology, and diabetes therapeutics globally. The company operates integrated manufacturing facilities and maintains a strong commitment to developing affordable healthcare solutions for patients in emerging markets worldwide.

Mumbai-based wealth and asset manager, formerly IIFL Wealth. India's largest listed wealth manager, with the PMS arm running 23 discretionary equity strategies for HNI and family-office capital. One of the largest equity PMS providers in India by AUM.